Research
Hormonal
Obesity increases the risk of post-menopausal breast cancer primarily through increased bioavailability of oestrogens due to adipose tissue aromatization and reduced sex hormone-binding globulin (SHBG).
For post-menopausal women, maintaining a healthy weight is crucial for reducing breast cancer risk. This risk is driven by higher levels of bioavailable oestrogens. If you are not using hormone replacement therapy, weight management is a key protective factor.
GoodSupportsHIGH confidence
obese post-menopausal women have higher conversion rates of sex hormones compared with non-obese post-menopausal women... obesity-related hyperinsulinaemia inhibits hepatic secretion of sex hormone-binding globulin... increase in bioavailable oestradiol and testosterone... may increase cell proliferation and inhibit apoptosis
Why this rating
Supported by multiple studies and biological plausibility, though epidemiological evidence for plasma levels of IGF-1 is noted as inconsistent.
Source
Obesity and cancer
Tobias Pischon et al. · Proceedings of The Nutrition Society · 2008
DOI 10.1017/s0029665108006976
narrative_reviewCited 322×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Abdominal obesity, measured by waist circumference or waist-to-hip ratio, is a stronger and more consistent predictor of colon cancer risk across genders than total body mass index (BMI).Good
- Abdominal obesity is a significant risk factor for endometrial cancer, with risk increasing in a dose-dependent manner with weight gain, largely mediated by 'unopposed estrogen' from increased bioavailable oestrogens and low progesterone.Good
- Obesity increases the risk of oesophageal adenocarcinoma, primarily through gastroesophageal reflux and oesophagitis, whereas it may have an inverse or neutral association with oesophageal squamous cell carcinoma.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →